769 related articles for article (PubMed ID: 25217457)
1. Three-year patient-related and stent-related outcomes of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice (from the Multicenter Prospective EXCELLENT and RESOLUTE-Korea Registries).
Lee JM; Park KW; Han JK; Yang HM; Kang HJ; Koo BK; Bae JW; Woo SI; Park JS; Jin DK; Jeon DW; Oh SK; Park JS; Kim DI; Hyon MS; Jeon HK; Lim DS; Kim MG; Rha SW; Her SH; Hwang JY; Kim S; Choi YJ; Kang JH; Moon KW; Jang Y; Kim HS
Am J Cardiol; 2014 Nov; 114(9):1329-38. PubMed ID: 25217457
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of second-generation everolimus-eluting Xience V stents versus zotarolimus-eluting resolute stents in real-world practice: patient-related and stent-related outcomes from the multicenter prospective EXCELLENT and RESOLUTE-Korea registries.
Park KW; Lee JM; Kang SH; Ahn HS; Yang HM; Lee HY; Kang HJ; Koo BK; Cho J; Gwon HC; Lee SY; Chae IH; Youn TJ; Chae JK; Han KR; Yu CW; Kim HS
J Am Coll Cardiol; 2013 Feb; 61(5):536-44. PubMed ID: 23273394
[TBL] [Abstract][Full Text] [Related]
3. Everolimus-eluting Xience v/Promus versus zotarolimus-eluting resolute stents in patients with diabetes mellitus.
Park KW; Lee JM; Kang SH; Ahn HS; Kang HJ; Koo BK; Rhew JY; Hwang SH; Lee SY; Kang TS; Kwak CH; Hong BK; Yu CW; Seong IW; Ahn T; Lee HC; Lim SW; Kim HS
JACC Cardiovasc Interv; 2014 May; 7(5):471-81. PubMed ID: 24852802
[TBL] [Abstract][Full Text] [Related]
4. 4-year clinical outcomes and predictors of repeat revascularization in patients treated with new-generation drug-eluting stents: a report from the RESOLUTE All-Comers trial (A Randomized Comparison of a Zotarolimus-Eluting Stent With an Everolimus-Eluting Stent for Percutaneous Coronary Intervention).
Taniwaki M; Stefanini GG; Silber S; Richardt G; Vranckx P; Serruys PW; Buszman PE; Kelbaek H; Windecker S;
J Am Coll Cardiol; 2014 Apr; 63(16):1617-25. PubMed ID: 24530680
[TBL] [Abstract][Full Text] [Related]
5. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
von Birgelen C; Basalus MW; Tandjung K; van Houwelingen KG; Stoel MG; Louwerenburg JH; Linssen GC; Saïd SA; Kleijne MA; Sen H; Löwik MM; van der Palen J; Verhorst PM; de Man FH
J Am Coll Cardiol; 2012 Apr; 59(15):1350-61. PubMed ID: 22341737
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.
Tandjung K; Sen H; Lam MK; Basalus MWZ; Louwerenburg JHW; Stoel MG; van Houwelingen KG; de Man FHAF; Linssen GCM; Saïd SAM; Nienhuis MB; Löwik MM; Verhorst PMJ; van der Palen J; von Birgelen C
J Am Coll Cardiol; 2013 Jun; 61(24):2406-2416. PubMed ID: 23602769
[TBL] [Abstract][Full Text] [Related]
7. Two-year clinical outcomes of patients with overlapping second-generation drug-eluting stents for treatment of long coronary artery lesions: comparison of everolimus-eluting stents with resolute zotarolimus-eluting stents.
Li XT; Sun H; Zhang DP; Xu L; Ni ZH; Xia K; Liu Y; Chi YH; He JF; Li WM; Wang HS; Wang LF; Yang XC
Coron Artery Dis; 2014 Aug; 25(5):405-11. PubMed ID: 24584031
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Resolute zotarolimus-eluting stents versus everolimus-eluting stents in patients with metabolic syndrome and acute myocardial infarction: propensity score-matched analysis.
Ji MS; Jeong MH; Ahn YK; Kim SH; Kim YJ; Chae SC; Hong TJ; Seong IW; Chae JK; Kim CJ; Cho MC; Rha SW; Bae JH; Seung KB; Park SJ; Hur SH;
Int J Cardiol; 2015 Nov; 199():53-62. PubMed ID: 26186631
[TBL] [Abstract][Full Text] [Related]
9. Comparison of 9-month angiographic outcomes of Resolute zotarolimus-eluting and everolimus-eluting stents in a real world setting of coronary intervention in Korea.
Lee JM; Youn TJ; Park JJ; Oh IY; Yoon CH; Suh JW; Cho YS; Cho GY; Chae IH; Choi DJ
BMC Cardiovasc Disord; 2013 Sep; 13():65. PubMed ID: 24011332
[TBL] [Abstract][Full Text] [Related]
10. Comparison of Resolute zotarolimus-eluting and Xience everolimus-eluting stents in patients with de novo long coronary artery lesions: a randomized LONG-DES VI trial.
Kang DY; Lee CH; Lee PH; Ahn JM; Lee SW; Kim YH; Park SW; Nam CW; Choi YS; Rha SW; Cho JH; Kim W; Her SH; Jeong MH; Yang JY; Lee BK; Park HS; Park DW; Park SJ
Coron Artery Dis; 2019 Jan; 30(1):59-66. PubMed ID: 30507632
[TBL] [Abstract][Full Text] [Related]
11. 5-Year Outcome Following Randomized Treatment of All-Comers With Zotarolimus-Eluting Resolute Integrity and Everolimus-Eluting PROMUS Element Coronary Stents: Final Report of the DUTCH PEERS (TWENTE II) Trial.
Zocca P; Kok MM; Tandjung K; Danse PW; Jessurun GAJ; Hautvast RWM; van Houwelingen KG; Stoel MG; Schramm AR; Tjon Joe Gin RM; de Man FHAF; Hartmann M; Louwerenburg JHW; Linssen GCM; Löwik MM; Doggen CJM; von Birgelen C
JACC Cardiovasc Interv; 2018 Mar; 11(5):462-469. PubMed ID: 29519378
[TBL] [Abstract][Full Text] [Related]
12. Long-term safety and efficacy of second-generation everolimus-eluting stents compared to other limus-eluting stents and bare metal stents in patients with acute coronary syndrome.
Omar A; Torguson R; Kitabata H; Pendyala LK; Loh JP; Magalhaes MA; Satler LF; Suddath WO; Pichard AD; Waksman R
Catheter Cardiovasc Interv; 2014 Dec; 84(7):1053-60. PubMed ID: 24619969
[TBL] [Abstract][Full Text] [Related]
13. Safety and Efficacy of Everolimus- Versus Sirolimus-Eluting Stents: 5-Year Results From SORT OUT IV.
Jensen LO; Thayssen P; Christiansen EH; Maeng M; Ravkilde J; Hansen KN; Hansen HS; Krusell L; Kaltoft A; Tilsted HH; Berencsi K; Junker A; Lassen JF;
J Am Coll Cardiol; 2016 Feb; 67(7):751-62. PubMed ID: 26892409
[TBL] [Abstract][Full Text] [Related]
14. Safety and efficacy of resolute zotarolimus-eluting stents compared with everolimus-eluting stents: a meta-analysis.
Piccolo R; Stefanini GG; Franzone A; Spitzer E; Blöchlinger S; Heg D; Jüni P; Windecker S
Circ Cardiovasc Interv; 2015 Apr; 8(4):. PubMed ID: 25858975
[TBL] [Abstract][Full Text] [Related]
15. Unrestricted randomised use of two new generation drug-eluting coronary stents: 2-year patient-related versus stent-related outcomes from the RESOLUTE All Comers trial.
Silber S; Windecker S; Vranckx P; Serruys PW;
Lancet; 2011 Apr; 377(9773):1241-7. PubMed ID: 21459430
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of the Resolute zotarolimus-eluting stent in patients with in-stent restenosis: 2-year results from a pooled analysis.
Richardt G; Leschke M; Abdel-Wahab M; Toelg R; El-Mawardy M; Serruys PW; Silber S; Windecker S; Belardi JA; Neumann FJ; Widimsky P; ;
JACC Cardiovasc Interv; 2013 Sep; 6(9):905-13. PubMed ID: 23954063
[TBL] [Abstract][Full Text] [Related]
17. Complex patients treated with zotarolimus-eluting resolute and everolimus-eluting Xience V stents in the randomized TWENTE trial: comparison of 2-year clinical outcome.
Sen H; Lam MK; Tandjung K; Löwik MM; Stoel MG; de Man FH; Louwerenburg JH; van Houwelingen GK; Linssen GC; Doggen CJ; Basalus MW; von Birgelen C
Catheter Cardiovasc Interv; 2015 Jan; 85(1):74-81. PubMed ID: 24585502
[TBL] [Abstract][Full Text] [Related]
18. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials.
Bangalore S; Kumar S; Fusaro M; Amoroso N; Attubato MJ; Feit F; Bhatt DL; Slater J
Circulation; 2012 Jun; 125(23):2873-91. PubMed ID: 22586281
[TBL] [Abstract][Full Text] [Related]
19. 1-Year Outcomes of Everolimus-Eluting Bioresorbable Scaffolds Versus Everolimus-Eluting Stents: A Propensity-Matched Comparison of the GHOST-EU and XIENCE V USA Registries.
Tamburino C; Capranzano P; Gori T; Latib A; Lesiak M; Nef H; Caramanno G; Naber C; Mehilli J; Di Mario C; Sabaté M; Münzel T; Colombo A; Araszkiewicz A; Wiebe J; Geraci S; Jensen C; Mattesini A; Brugaletta S; Capodanno D
JACC Cardiovasc Interv; 2016 Mar; 9(5):440-9. PubMed ID: 26875648
[TBL] [Abstract][Full Text] [Related]
20. Comparison of 2-year outcomes between zotarolimus-eluting and everolimus-eluting new-generation cobalt-chromium alloy stents in real-world diabetic patients.
Miyazaki T; Latib A; Panoulas VF; Miyazaki S; Costopoulos C; Sato K; Naganuma T; Kawamoto H; Daida H; Colombo A
Catheter Cardiovasc Interv; 2015 Jul; 86(1):E11-8. PubMed ID: 25534499
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
